U.S. Patent No. 10,098,867 B2 (‘867) issued on October 16, 2018, for “Use of Phytocannabinoids in the Treatment of Ovarian Carcinoma.” It was issued to applicant GW Research Ltd. of Cambridge, Great Britain, the research division of the cannabinoid-based pharmaceutical company GW Pharmaceuticals, plc. The inventors are Farideh Afshin Javid of Huddersfield, Great Britain, Marnie Duncan, and Colin Stott, both of Cambridge, Great Britain.
The ‘867 claims are directed to a method to treat ovarian cancer through a compound comprising cannabidiol (CBD) and cannabigerol (CBG). Further limitations are directed to the extracted or botanical form of the CBD/CBG compound, as well as its isolated form. The disclosure indicates that due to the numerous side effects related to chemotherapy and other conventional methods for treating cancer, phytocannabinoid research has found apoptosis (i.e., cell death) of carcinoma cells. The specification further discloses several embodiments of the phytocannabinoid combinations, including CBD, CBG, CBDA, CBGA, CGBV, and THCV. These are non-psychoactive elements of the cannabis plant.
The International Patent Classification is A61K (preparations for medical, dental purposes, namely (31/352/31/353) heterocyclic compounds having six-membered rings with one oxygen as the only ring hetero atom condensed with carboxylic rings (e.g., canabinols) and 3,4-Dihydrobenzopyrans (e.g., catechin), (31/192) carboxylic acids having aromatic grounds (e.g., ethacrynic acid), (36/185) magnoliophyta, and (45/06) medical preparations containing active ingredients not provided for in other groups, including mixtures of active ingredients without chemical characterization).
GW Pharma holds numerous patents on various cannabis-related pharmaceutical drugs, including methods, therapeutic uses, compositions, and manufactures of uses. Please contact Yonaxis for more additional information on the patent processes described in this posting if you have any questions.